News & Analysis on Clinical Trial Services & Contract Research And Development
US diabetics will soon have a new alternative to the predominant needle and syringe method of administering insulin, now that the Food and Drug Administration (FDA) has granted marketing approval to Sanofi-Aventis' Lantus SoloStar.
A new machine developed by US firm Vardex Laser promises to offer a unique solution to the global problem of drug counterfeiting, protecting products right down to the pill itself.
The US Biotechnology Industry Organisation (BIO) has fuelled even further the ongoing debate over the potential approval path for follow-on biologics in the country with the release of a white paper this week that stressed that 'generic' versions of...
Danish drugmaker Novo Nordisk is investing $200 million (€146.5m) in a major expansion of its insulin production facilities in Montes Claros, Brazil.
Active packaging specialist Multisorb Technologies is in the midst of developing a new desiccant product that will offer a novel built-in solution to producers of dry powder and metered dose inhalers.
The UK has upheld its promise to crack down on its problem of animal rights extremism, arresting 30 people in dawn raids across the country yesterday as part of 'Operation Achilles'.
A 'homing' protein fragment that can track down tumours in the body has been developed to deliver imaging agents or anticancer therapies to cells.
A group of Swedish scientists have discovered a new method of disabling genes that could be used to stop genetic disorders in their tracks, such as Huntington's and some cancers.
Pressure BioSciences (PBI) is set to release a new lightweight version of its pressure cycling instrument to control biomolecular interactions, after a downsized demo model proved surprisingly popular.
The pharma industry sees great opportunities in using Radio Frequency Identification (RFID) technology during clinical trials, a new survey has revealed.
West Pharmaceutical Services reported a 40 per cent increase in operating profit for the first quarter of 2007, despite profits diving 43 per cent in the Tech Group business that makes the delivery device for Pfizer's inhaled insulin Exubera.
Italian glassware specialist Stevanato Group has consolidated the engineering side of its business through the acquisition of fellow Italian company Optrel.
The twelfth in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.